1. What Is the PET Scan Market?
The PET Scan Market covers the positron emission tomography imaging systems that detect the gamma ray pairs emitted by the annihilation of positrons from fluorine-18 labelled radiopharmaceuticals. The systems produce the metabolic functional images of glucose uptake, amyloid accumulation, receptor density, and blood flow. The oncology staging, neurology assessment, and cardiac viability evaluation use these to characterise the biological function that anatomical CT and MRI imaging cannot provide from tissue morphology alone. PET scanner design uses the ring of scintillator detectors surrounding the patient table that simultaneously detect the coincident gamma ray pairs from each positron annihilation event. The system reconstructs the three-dimensional activity distribution within the patient from the detected coincidence events using iterative reconstruction algorithms. FDG PET/CT supports the initial staging and treatment response monitoring of the majority of solid tumours and lymphomas. Amyloid PET detects the amyloid beta plaques confirming Alzheimer's disease diagnosis. PSMA PET supports the staging and recurrence detection of prostate cancer displacing bone scan and CT. These represent the primary clinical PET applications driving scanner procurement and radiopharmaceutical production.
2. PET Scan Market Size & Forecast
3. Emerging Technologies
- Total body PET scanners from United Imaging uEXPLORER and Siemens Biograph Vision Quadra use a 1 to 2-metre axial field of view that captures the entire body simultaneously. The scanners achieve 40-fold sensitivity improvement over conventional PET. The improvement enables ultra-low dose imaging and dynamic whole-body kinetic modelling. The modelling reveals the drug distribution and pharmacokinetics of labelled compounds throughout the entire body.
- PSMA PET/CT with gallium-68 PSMA-11 and fluorine-18 labelled PSMA ligands demonstrates superior sensitivity and specificity for prostate cancer lymph node metastasis detection compared with conventional CT and bone scan. The evidence drove FDA approval of two PSMA PET radiopharmaceuticals. The guideline revision recommends PSMA PET as the preferred staging modality for intermediate and high-risk prostate cancer before radical treatment.
- Tau PET tracers targeting the neurofibrillary tangle pathology of Alzheimer's disease and other tauopathies provide the in vivo measurement of tau burden distribution. The measurement differentiates Alzheimer's from other dementia syndromes and correlates with clinical disease severity. The biological staging information complements the amyloid PET for the complete assessment of Alzheimer's disease pathology.
- Digital silicon photomultiplier detector technology in the Philips Vereos and GE Omni Legend PET systems replaces analogue photomultiplier tubes with solid-state silicon photomultiplier detectors. The digital SiPM improves the time-of-flight resolution and energy resolution compared with analogue PMT. The technology provides the improved image quality and reduced patient dose that digital PET detector technology enables.
Such innovations are driving change across adjacent industries too. Discover more in our Mri Market.
4. Key Market Opportunity
Meaningful upside in the PET Scan market comes from PSMA PET rapid adoption in prostate cancer displacing conventional imaging, where the superior staging performance drives prescribing transitions across urology and oncology practice. Lantheus and Blue Earth Diagnostics (Bracco) capture this PSMA PET prescribing opportunity. Complementary growth involves amyloid and tau PET expansion alongside anti-amyloid drug launches. As PSMA PET adoption proceeds and amyloid-tau PET expands with lecanemab prescribing, the addressable opportunity is expanding from FDG-dominant oncology PET toward disease-specific PET tracers.
5. Top Companies in the PET Scan Market
The following organisations hold leading positions in the PET Scan Market. The full report provides revenue share, SWOT analysis, and competitive benchmarking for each player.
- Siemens Healthineers
- GE HealthCare
- Philips
- Canon
- United Imaging
- Mediso
- Bruker
- PerkinElmer
- Cubresa
6. Market Segmentation
The PET Scan Market is analysed across 4 segmentation dimensions. Revenue data, growth rates, and competitive intensity by sub-segment are available in the full report.
| Segmentation | Sub-Segments |
|---|---|
| By System Type | PET-CTPET-MRIDigital PETStandalone PET |
| By Radiopharmaceutical | FDGAmyloidTauPSMADOTATATE |
| By Application | Oncology StagingNeurologyCardiology |
| By Geography | North AmericaEuropeAsia PacificLatin AmericaMiddle East and Africa |
7. Key Market Trends (2026–2034)
Three major forces are shaping the PET Scan Market trajectory over the forecast period:
Total Body PET Scanners With 1 to 2-Metre Axial Field of View Achieving 40-Fold Sensitivity Improvement Are Enabling Ultra-Low-Dose Imaging and Simultaneous Whole-Body Kinetic Drug Distribution Modelling That Conventional PET Cannot Provide.The whole-body FDG-PET CT scan that takes 20-30 minutes and provides staging information from head to toe has become the standard staging examination for Hodgkin lymphoma, non-Hodgkin lymphoma, lung cancer, and colorectal cancer recurrence evaluation where the PET metabolic characterisation of lesions across the body is required for accurate staging. Siemens, GE Healthcare, and Philips supply the 90 percent of global PET-CT scanners that use lutetium oxyorthosilicate scintillator crystals and silicon photomultiplier detector technology that provides the sensitivity and timing resolution required for whole-body PET imaging at the radiation doses acceptable in clinical practice. The FDG radiopharmaceutical supply chain requiring on-site cyclotron production or regional distribution within the 110-minute F-18 half-life has created the regional PET radiopharmacy infrastructure that makes clinical PET accessible to hospitals within delivery range of a regional cyclotron facility.
PSMA PET/CT Superior Sensitivity for Prostate Cancer Lymph Node Metastasis Has Driven FDA Approval and Guideline Recommendation as the Preferred Staging Modality for Intermediate and High-Risk Prostate Cancer Before Radical Treatment.The uEXPLORER total-body PET system from United Imaging Healthcare covering 194 cm axial length and the Biograph Vision Quadra from Siemens with 106 cm axial coverage provide the total-body PET scanner platforms that research centres use for the pharmacokinetic modelling of drug distribution, whole-body kinetic imaging, and the dynamic PET studies that require simultaneous measurement of tracer uptake across all organs. The total-body PET sensitivity advantage of 40-50 times greater than conventional PET enables either 40-fold dose reduction for the same image quality or 40-fold scan time reduction for equivalent dose, enabling the paediatric and research volunteer PET imaging at radiation doses that conventional PET cannot achieve. The total-body PET commercial market has expanded from the initial research centre installations to include clinical PET facilities where the dose reduction benefit for paediatric patients and the improved detection sensitivity for low-uptake lesions justify the higher capital investment.
Silicon Photomultiplier Digital PET Detectors Replacing Analogue PMTs Are Improving Time-of-Flight Resolution to Deliver the Image Quality Improvement and Patient Dose Reduction That Digital Detector Technology Enables.Specifically designed brain PET scanners from Siemens and General Electric with 1-2 mm spatial resolution provide the neuroimaging capability for quantitative amyloid and tau PET studies in Alzheimer's disease research that whole-body PET spatial resolution cannot achieve for the small cortical and subcortical structures of interest. The dedicated breast PET scanner from Naviscan that places the detector plates close to the breast tissue provides the 1.5-2 mm resolution and high sensitivity for small lesion detection that standard whole-body PET cannot achieve for the breast imaging application where conventional PET is limited by the limited spatial resolution relative to breast lesion sizes. The prostate-specific PET imaging using PSMA-targeted radiopharmaceuticals in whole-body PET systems has driven the clinical utility of PET for prostate cancer staging and recurrence evaluation beyond the FDG-PET indication, establishing the disease-specific radiotracer development as the key driver of PET clinical adoption growth across oncology indications.
For related market intelligence, see the Nuclear Medicine Market.
8. Segmental Analysis
By system type, the digital PET and time-of-flight PET segment dominated the PET Scan Market in 2025, as Siemens Biograph Vision and GE Discovery MI anchored oncology and neurology imaging at academic medical centres, generating the dominant share of PET system revenue.
By radiopharmaceutical, the next-generation theranostic and tau-imaging agent segment is projected to register the highest growth rate through 2034, as Novartis Lutetium-177 and Eli Lilly tau-PET tracers drive PET scan volumes in therapeutic response monitoring and Alzheimer disease staging beyond conventional FDG-oncology indications.
9. Regional Analysis
Regional demand patterns across the PET Scan Market reflect differences in regulation, technological maturity, and capital investment.
Largest Market Share
North America dominated the PET Scan Market in 2025, accounting for approximately 47% of global revenue, attributed to US premium pricing for PSMA PET tracers and digital PET-CT systems and the rapid PSMA PET adoption in prostate cancer restaging. Moreover, amyloid PET prescribing for Alzheimer's diagnosis is most advanced in the US. In addition, FDG PET-CT oncology staging is established. Regional dominance is due to this combination of pricing environment and novel tracer adoption.
Highest CAGR Region
Europe is projected to register the highest CAGR in the PET Scan Market through 2034, driven by expanding PSMA PET and amyloid PET access across European healthcare systems and the active European clinical trial infrastructure in nuclear medicine. The region is also witnessing digital PET technology adoption growing. Moreover, DOTATATE PET neuroendocrine tumour staging is expanding. The combination of these demand drivers and access expansion positions Europe for sustained growth outperformance through 2034.
10. Full Report with Exclusive Insights
The complete published market report includes an in-depth analysis of market dynamics, industry trends, competitive landscape, regional outlook, and future growth opportunities. The study provides detailed market sizing and forecasts across key segments and geographies, along with comprehensive insights into drivers, restraints, opportunities, challenges, technological advancements, regulatory landscape, and evolving consumer and industry trends. The report also features company profiles, strategic developments, market share analysis, and actionable recommendations to support informed business decision-making. Additionally, the syndicated report package typically includes forecast datasets, charts and figures, research methodology, and analyst support for strategic interpretation and planning.
Advanced Strategic & Custom Intelligence
In addition to the standard syndicated report package, TrendX Insights can provide the following advanced strategic analyses and customized intelligence solutions for any market:
Standard Report Coverage
- • Competitor Analysis
- • Country Trade Analysis
- • Import & Export Analysis
- • Porter’s Five Forces Analysis
- • SWOT Analysis by Companies
- • TrendX Insights Quadrant Positioning
- • Pricing Analysis
- • Detailed Macro-Economic Indicators Assessment
- • List of Raw Material Suppliers
- • Regulatory Framework Assessment
- • Supply Chain Resilience Mapping
- • Value Chain Analysis
- • Technology adoption trends and innovation tracking
- • Custom company profiling and benchmarking
Exclusive Sections With Additional Cost
- • Agentic AI Readiness Score
- • TAM, SAM, and SOM Analysis
- • AI Act & Privacy Compliance Audit
- • Channel Partner Ecosystem Mapping
- • China + 1 Strategy Analysis
- • Circular Economy Opportunities Assessment
- • Competitor Benchmarking KPI Analysis
- • Country Trade Analysis
- • Country-level opportunity mapping
- • Digital Maturity Matrix
- • Ecosystem Interdependency Mapping
- • ESG & Decarbonization Roadmap
- • Geopolitical Friction Scorecard
- • Geopolitical Risk Assessment
- • Humanoid Workforce Impact Analysis
- • Investment Heatmap
- • List of Distributors and Channel Partners
- • List of Raw Material Suppliers
- • Market Entry Strategy Assessment
- • Mergers & Acquisitions (M&A) Analysis
- • Patent & Intellectual Property (IP) Analysis
- • Pilot Project Analysis
- • Potential High-Growth Region/Country Investment Assessment
- • Product Comparison Analysis
- • Product Revenue Analysis
- • R&D Investment Analysis in Emerging Technologies
- • Raw Material Scarcity Forecast
Note: For highly customized requirements, deeper strategic assessments, company-specific intelligence, or tailored consulting support, please contact TrendX Insights.
Full Report with Exclusive Insights
Available to clients on request
Explore Our Published Reports Library
This page covers market-level data estimates. For comprehensive published research reports including full methodology, primary data, and detailed company profiles, browse the TrendX Insights Published Reports Library.
Visit Published Reports Library ›11. Related Market Reports
Frequently Asked Questions
The PET Scan Market was valued at USD 2.89 Bn in 2025 and is projected to reach USD 6.71 Bn by 2034, growing at a CAGR of 9.8% over the 2026–2034 forecast period.
The PET Scan Market is projected to grow at a CAGR of 9.8% from 2026 to 2034.
North America dominated the PET Scan Market in 2025, accounting for approximately 47% of global revenue, attributed to US premium pricing for PSMA PET tracers and digital PET-CT systems and the rapid PSMA PET adoption in prostate cancer restaging.
The leading companies in the PET Scan Market include Siemens Healthineers, GE HealthCare, Philips, Canon, United Imaging, Mediso, Bruker, PerkinElmer, Cubresa.
Total body pet scanners with 1 to 2-metre axial field of view achieving 40-fold sensitivity improvement are enabling ultra-low-dose imaging and simultaneous whole-body kinetic drug distribution modelling that conventional pet cannot provide.
By system type, the digital PET and time-of-flight PET segment dominated the PET Scan Market in 2025, as Siemens Biograph Vision and GE Discovery MI anchored oncology and neurology imaging at academic medical centres, generating the dominant share of PET system revenue.
How to Order
Purchasing a TrendX Insights report is straightforward. Our process is designed to be transparent and risk-free for buyers, with a 20% upfront model and full delivery before the balance payment.
This is the price of the syndicated report. Any custom inclusions beyond the Table of Contents will be scoped and priced separately. For the full list of what is covered in the syndicated report, refer to the Table of Contents tab.
A curated, condensed version of this report for students, researchers, and academic institutions. Ideal for thesis work, dissertations, and academic projects. Delivered as PDF to your institutional email.
Valid student ID or institutional email required. For educational and non-commercial use only.